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Systemic lupus erythematosus (SLE) is a systemic autoimmune syndrome defined by clinical and
serologic features, including arthritis, glomerulonephritis, and certain autoantibodies such as anti-
nuclear ribonucleoprotein (nRNP)/Smith antigen (Sm), DNA, and ribosomal P. Although lupus is
considered primarily a genetic disorder, we recently demonstrated the induction of a syndrome
strikingly similar to spontaneous lupus in many nonautoimmune strains of mice exposed to the
isoprenoid alkane pristane (2,6,10,14-tetramethylpentadecane), a component of mineral oil.
Intraperitoneal injection of pristane leads to the formation of lipogranulomas consisting of
phagocytic cells that have engulfed the oil and collections of lymphocytes. Subsequently, pristane-
treated BALB/c and SJL mice develop autoantibodies characteristic of SLE, including anti-nRNP/Sm,
antiribosomal P, anti-Su, antichromatin, anti-single-stranded DNA, and anti-double-stranded DNA.
This is accompanied by a severe glomerulonephritis with immune complex deposition, mesangial or
mesangiocapillary proliferation, and proteinuria. All inbred mice examined appear to be susceptible
to this novel form of chemically induced lupus. Pristane-induced lupus is the only inducible model of
autoimmunity associated with the clinical syndrome as well as with the characteristic serologic
abnormalities of SLE. Defining the immunopathogenesis of pristane-induced lupus in mice may
provide insight into the causes of spontaneous (idiopathic) lupus and also may lead to information
concerning possible risks associated with the ingestion or inhalation of mineral oil and exposure to
hydrocarbons in the environment. Key words: alkanes, autoantibodies, autoimmunity,
hydrocarbons, mineral oil, mouse models, pristane, systemic lupus erythematosus. - Environ
Health Perspect 107(suppl 5):723-727 (1999).
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Systemic lupus erythematosus (SLE) is an
idiopathic autoimmune syndrome influenced
by both genetic and environmental factors
and characterized immunologically by the
development of autoantibodies directed
against self-nuclear, nucleolar, and cytoplas-
mic antigens (1). Autoantibodies produced in
SLE that serve as subset-specific disease mark-
ers include anti-Smith antigen (Sm), antiribo-
somal P, and anti-double-stranded DNA
(anti-dsDNA). Other antibodies associated
with SLE, such as anti-nuclear ribonucleo-
protein (nRNP), anti-single stranded DNA
(anti-ssDNA), antichromatin, antihistone,
and anti-Su are less subset specific. SLE is
defined clinically by a spectrum ofabnormali-
ties such as skin rashes (malar rash, photosen-
sitivity, discoid lesions), nonerosive arthritis,
serositis, central nervous system involvement
(seizures, psychosis, and other manifesta-
tions), and immune complex-mediated
glomerulonephritis (2). A similar syndrome
develops spontaneously in (NZB x NZW)F1
mice (3). Although a useful model for SLE,
the lupuslike disease in these mice is not asso-
ciated with arthritis, serositis, rashes, or some
of the characteristic serological abnormalities
(anti-Sm and antiribosomal P autoantibodies)
(Table 1).
Certain medications, notably procain-
amide, quinidine, hydralazine, methyldopa,
and isoniazid, induce a syndrome in humans
that resembles idiopathic lupus (4). Drug-
induced lupus is associated with arthritis,
serositis, and other manifestations ofSLE but
not with glomerulonephritis (5) (Table 1).
Autoantibodies to a subset ofantigens (anti-
ssDNA, -chromatin, -histone) also are pro-
duced (6), whereas the marker autoantibodies
anti-dsDNA, anti-Sm, and antiribosomal P
are not. Thus, although similar in some
respects to idiopathic lupus, both the lupus-
like syndrome in (NZB x NZW)F1 mice and
drug-induced lupus differ from SLE in key
respects (Table 1).
Our laboratory has established a mouse
model in which a lupuslike syndrome is
induced by a single intraperitoneal (ip) injec-
tion ofpristane (2,6,10,14-tetramethylpen-
tadecane) (7,8). All inbred strains of mice
tested so far are susceptible. As indicated in
Table 1, the lupuslike syndrome developing
in pristane-treated mice closely resembles
idiopathic SLE. Pristane-treated mice develop
a strikingly similar immune complex disease
with severe glomerulonephritis (8). Although
arthritis develops in some strains, it is erosive
and therefore more reminiscent ofrheuma-
toid arthritis than SLE (9,10). In addition,
pristane treatment induces the marker
autoantibodies characteristic ofSLE, induding
anti-dsDNA, anti-Sm, and antiribosomal P
along with a variety ofother lupus-associated
autoantibodies that includes antihistone,
antichromatin, and anti-Su (7,11,12). Thus,
pristane-induced lupus appears to mimic the
human idiopathic lupus syndrome more
closely than either drug-induced lupus or the
lupuslike syndrome of (NZB x NZW)F1
mice. Significantly, pristane is the first
chemical to induce a true SLE syndrome
with both characteristic autoantibodies and
immune complex disease. Moreover, human
exposure to pristane and related hydro-
carbons is widespread (13-17), making -
pristane-induced lupus a useful model for




Female SJL/J and BALB/c mice 4 weeks of
age were purchased from Jackson Laboratory
(Bar Harbor, ME) and housed in a conven-
tional animal facility. At 10 weeks ofage,
SJL/J and BALB/cByJ mice received a single
injection (0.5 mL, ip) of pristane or sterile
phosphate-buffered saline (PBS). Sera were
collected from the tail vein before injection at
1, 2, and 4 weeks afterward and at 1-month
intervals thereafter. Urine samples were tested
monthly for protein concentration using
Albustix reagent strips (Miles Laboratories,
Elkhart, IN). Additional SJL and BALB/c ByJ
mice were injected with HgCI2 (1.6 mg/kg
subcutaneously twice weekly) or with sterile
PBS for 8 weeks (18). The care and treatment
ofanimals in this study were in compliance
with all applicable federal and state regula-
tions. The University ofNorth Carolina at
Chapel Hill is an Association for the
Assessment and Accreditation ofLaboratory
Care (AAAIAC)-accredited institution.
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Immunopreapitation
K562 (human erythroleukemia) cells
(American Type Culture Collection,
Rockville, MD) were radiolabeled with
[35S]methionine, and cell extracts were
immunoprecipitated using murine sera as
described (7). Human prototype sera specific
for nRNP, Sm, or Su antigens were obtained
with informed consent and used as standards.
Immunoprecipitated proteins were analyzed




to nuclear and cytoplasmic antigens was per-
formed usingmethanol-fixed HeLa cells (11).
Cells were incubated for 30 min with 1:40
murine serum in blocking buffer (10% calf
serum in PBS), washed 3 times with PBS,
thenincubatedfor30 minwith 1:40fluorocein
isothiocyanate-conjugated goat anti-mouse
IgG (y-chain-specific; Southern Biotech-
nology Associates, Birmingham, AL). After
another washing, the cells were viewed with
an epifluorescence microscope.
Histopathology
Peritoneal tissue sections were removed from
pristane-treated BALB/c mice 7 months
after treatment. For light microscopy, tissue
was fixed in 4% paraformaldehyde and




Intraperitoneal injection ofpristane is followed
by engulfment ofthe oil by phagocytic cells.
Table 1. Comparison ofspontaneous and chemicallyinduced lupus.
Spontaneous lupus Chemically induced lupus
Manifestation Systemic lupuserythematosus (NZBx NZW)F1 Procainamide Pristane
Arthritis + + +a
Serositis + - + +
Rash +
Nephritis + + - +
AntinuclearAbs + + + +
Anti-Sm + +
Anti-dsDNA + + +
Antiribosomal P + - - +
Abbreviations: anti-dsDNA, anti-double-stranded DNA; anti-Sm, anti-Smith antigen. Erosive arthritis.
Figure 1. Pristane granuloma. Hematoxylin-eosin staining ofa lipogranuloma attachedtothe peritoneal mesothelium
of a BALB/c mouse injected 6 months earlierwith pristane (0.5 mL intraperitoneally). (A) Low-powerview showing
abdominal skeletal muscle on either side of the centrally located polypoid lipogranuloma. Original magnification
100x. (B) High-power view showing oil droplets of various sizes within the lipogranuloma. Note the flattened,
epithelioid cells encapsulating the larger oil droplets. Original magnification 400x. (C) High-power view showing
lymphocytic infiltrate in the vicinity of multiple small oil droplets contained within the lipogranuloma. Original
magnification 400x.
The phagocytes become organized into
polyplike structures or lipogranulomas
(19,20). A typical lipogranuloma from a
pristane-treated BALB/c mouse is illustrated
in Figure IA. Large polypoid masses adherent
to the serosal surface ofthe peritoneal cavity
are apparent. Numerous oil droplets are seen
within these masses and are shown at higher
power in Figure lB. Although pristane
droplets are taken up into macrophages by
phagocytosis (20), many ofthe droplets illus-
trated in Figure 1B are considerably larger
than a cell. Palisading ofcells surrounding
these large oil droplets is readily apparent.
This pattem is very reminiscent oftheorgani-
zation ofepithelioid macrophages around
large foreign bodies, including certain bio-
materials such assilicone implants (21).
Like pristane, the tissue reaction to
silicone gel is characterized by poorly orga-
nized granulomas with cystic spaces, presum-
ably containing the foreign material (22).
Silicone granulomas are in many respects typi-
cal foreign body-type granulomas, containing
aggregates ofepithelioid macrophages sur-
rounded by dense infiltrates oflymphocytes
and neutrophils. Lymphocytic infiltrates also
are apparent in pristane granulomas (Figure
1C). Plasma cells are prominent in these
lesions and in BALB/c mice may develop into
plasmacytomas (19). Plasma cells also may be
prominent insiliconegranulomas (23).
The pathogenesis ofoil granulomas is
incompletely understood. However, inviewof
the hydrophobicity ofpristane, some similari-
tieswith the inflammatoryresponse tosilicone
and other hydrophobic biomaterials may be
expected. The initial event is likely to be the
interaction ofplasmaproteins, such asfibrino-
gen, with the material (24,25). Subsequently,
additional host proteins bind to the mono-
layer ofpartially denatured proteins coating
the material. The adsorbed proteins may play
a crucial role in recruiting inflammatory cells.
The rapid binding ofC3b to a hydrophobic
foreign material is followed by conversion to
the hemolytically inactive, but still opsonic,
iC3b form (26). Phagocytic cells such as
monocytes and macrophages can recognize
diverse foreign molecules through a variety of
pattern receptors, including receptors for
complement component C3 andfibrinogen-
two ofthe proteins that bind tightly to the
surfaces ofbiopolymers. Complement recep-
tor 3 (CR3, CD11b/CD18, Mac-1), a recep-
tor for iC3B, appears to play a critical role in
the attachment ofmonocytes or other phago-
cytic cells to hydrophobic materials (26).
Fibrinogen, another serum protein that
adsorbs to foreign bodies, also is a ligand for
CR3 (27) and may play a role in the
recruitment ofinflammatorycells (28).
In addition to CR3, macrophage class A
scavenger receptors (29) are involved in the
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adherence ofmacrophage cell lines to serum-
coated polystyrene wells, and therefore also
could play a role in the recognition offoreign
materials such as pristane (30). Ligation of
macrophage Fc receptors, CR3, or scavenger
receptors can have important effects on
macrophage activation (31,32). In view of
the apparent coating ofpristane oil droplets
by epithelioid cells (Figure iB), it will be of
interest to investigate the role ofCR3, scav-
enger receptors, and other macrophage sur-
face receptors mediating innate immunity in
the development oflipogranulomas in pris-
tane-treated mice. Recent studies in our labo-
ratory suggest that macrophages in these
lesions are the likely source of several
cytokines critical for the development of
autoimmunity in pristane-treated mice,
notablyinterleukin (IL)-6 and IL-12 (12,33).
Further studies will be necessary, however, to
establish the mechanism by which these




Intraperitoneal injection of pristane is
associated with two phases ofautoantibody
production (8). IgM anti-ssDNAand antihis-
tone autoantibodies predominate during the
early phase, occurring approximately 2 weeks
after treatment. These autoantibodies are not
lupus specific. In contrast, lupus-specific
autoantibodies such as anti-dsDNA, anti-Sm,
and antiribosomal P are generated during the
late phase, 2-6 months after treatment.
Interestingly, the autoantibody specificities
vary between strains. For example, sera from
pristane-treated BALB/c and SJL mice exhibit
distinct patterns ofstaining in immunofluores-
cence assays (11) (Figure 2). Sera from
BALB/c mice treated 6 months earlier with
pristane displayed predominantly speckled
nudear staining, sparing the nudeoli (Figure
2A). In contrast, serafrompristane-treated SJL
mice stained the cytoplasm intensely, with
only weak nuclear staining (Figure 2B),
whereas sera from PBS-treated SJL mice ofthe
same age did not stain (Figure 2D). The SJL
strain is of particular interest due to its
predilection to produceantifibrillarin autoanti-
bodies in response to mercuric chloride treat-
ment (34,35). Antifibrillarin autoantibodies
were associatedwith nudeolar immunofluores-
cence, as illustrated in Figure 2C. Thus, two
chemicals, mercuric chloride and pristane,
induced very different types ofautoantibodies
in SJL mice, as indicated by immunofluores-
cence assays. Pristane-treated animals devel-
oped autoantibodies primarily directed at one
or more cytoplasmic antigens (Figure 2B),
whereas mercuric chloride-treated mice devel-
oped autoantibodies specific for the nucleolar
autoantigen fibrillarin (Figure2C).
Thedifferentpatternsofautoantibody pro-
duction in BALB/c versus those in SJL mice
suggested byimmunofluorescence studies were
confirmed by immunoprecipitation assays
(Figure 3). Sera from BALB/c mice immuno-
precipitated a group ofproteins comigrating
with proteins immunoprecipitated byahuman
I
anti-nRNP reference serum and designated A,
B'IB, C, D, ElF, andG. Theyarecomponents
ofthe Ul small nuclear ribonucleoprotein
(snRNP) particle, a complex ofall ofthese
proteins with a single molecule ofU1 small
nuclear RNA (36,37). The Ul snRNP can
be immunoprecipitated as a particle both by _!. _w^..,.,,
_E .
; .s;r 1 iSv
x _ ' ssE' b: ;5Di
i , ;:: s::.y
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Figure 2. Indirect immunofluorescence. Indirect immunofluorescence of autoantibodies to nuclear and cytoplasmic
antigens was performed using methanol-fixed HeLa cells as substrate (11). Mouse sera weretested ata 1:40 dilution
and binding of autoantibodies was detected using fluorescein isothiocyanate-conjugated goat antimouse IgG
(-chain-specific, 1:40 dilution). (A) Serum from a pristane-treated BALB/c mouse. (B) Serum from a pristane-treated
SJL mouse. (C) Serum from a mercuric chloride-treated SJL mouse. (D) Serum from a saline-treated SJL mouse. Sera
were obtained 6 months aftertreatment.
Human BALBIc SJL/J














Figure3. Determination ofautoantibody specificities by immunoprecipitation. Sera from pristane-treated BALB/c and
SJL mice were tested for immunoprecipitation of radiolabeled proteins from K562 cells (7). BALB/c sera (n = 5)
immunoprecipitated protein components of Ul small nuclear ribonucleoproteins (snRNPs) (A, B'/B. C, D, E/F, G) as
well as the 100/102-kDa Su antigens. In contrast, SJL sera (n = 5) immunoprecipitated the ribosomal P antigens P0,
P1, and P2. Lane 6 shows immunoprecipitation using serum from a phosphate-buffered saline-treated SJL mouse
(negative control). Immunoprecipitates using human reference sera containing anti-Su, nuclear ribonucleoprotein
antigen(anti-nRNP)(specific forcomponents ofthe Ul snRNP), or antiribosomal P(r-P) are shown on the leftforcom-
parison. Positions of molecularweightmarkers are indicated onthe right.
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anti-nRNP and by anti-Sm autoantibodies.
Pristane-treated BALB/c mice produce both
anti-nRNP and anti-Sm autoantibodies (38),
and their sera immunoprecipitate the Ul
snRNP particle specifically (Figure 3).
Pristane-treated BALB/c mice produce addi-
tional lupus-associated autoantibodies, includ-
ing anti-Su (100/102-kDa doublet) (Figure 3)
as well as anti-dsDNA, anti-ssDNA, and
antichromatin (12). Titers ofthese autoanti-
bodies can be as high as in human lupus (39).
In striking contrast, sera from pristane-treated
SJL mice immunoprecipitated agroup ofthree
polypeptides that comigrate with the ribo-
somal P0, P1, and P2 proteins recognized by
human reference serum with antiribosomal P
autoantibodies (Figure 3, right panel, lanes
1-5). SJL sera did not immunoprecipitate
components of the Ul snRNP, whereas
BALB/c sera did not immunoprecipitate P0,
P1, or P2. Serum from asaline-treated control
SJL mouse failed to immunoprecipitate any of
theproteins (Figure 3, rightpanel, lane6).
Autoantibody production by pristane-
treated mice is highly cytokine dependent
(12). IL-6 plays a critical role in the pro-
duction ofanti-dsDNA and antichromatin
autoantibodies but has less effect on anti-
nRNP/Sm and anti-Su autoantibody pro-
duction in this model. IL-6 is a pleiotropic
cytokine thought to be of pivotal impor-
tance to immune regulation through its
action on B and T cells (40). It is produced
in large quantities by macrophages that have
engulfed pristane and serves as a key
plasmacytoma growth factor (41,42). As in
pristane-induced lupus, IL-6 also has been
implicated in the pathogenesis ofanti-DNA
antibodies and nephritis in (NZB x
NZW)F1 mice (43). Interestingly, patients
with IL-6-secreting tumors such as atrial
myxomas produce autoantibodies (44).
In addition, microbial stimulation appears
to be an important cofactor in the induction
ofautoantibodies by pristane, as the disease is
milder in specific pathogen-free mice (housed
in barrier cages with autoclaved food, water,
and bedding) than in conventionally housed
animals (45). Not only are pathogen-free
BALB/c mice less susceptible to the develop-
ment oflupuslike disease, they also are refrac-
tory to plasmacytoma induction by pristane
(46). The mechanism ofthis effect remains
unclear but could reflect stimulation of
cytokine production by microbial products





In addition to autoantibodies characteristic
ofSLE, BALB/c and SJL mice treated with
pristane develop renal lesions strongly
resembling lupus nephritis (8,11). These are
characterized by glomerular deposition of
IgG, IgM, and complement, and marked
mesangial hypercellularity progressing to
severe mesangiocapillary lesions. Significant
proteinuria develops in association with the
evolution of mesangiocapillary lesions.
Although anti-dsDNA autoantibodies are
implicated in the pathogenesis of lupus
nephritis, the renal lesions in pristane-treated
mice develop well before the onset ofanti-
dsDNA autoantibody production. Their
pathogenesis currently is being investigated.
The induction of severe nephritis sets
pristane-induced lupus apart from other
forms ofchemically induced lupuslike disease
such as procainamide-induced lupus in which
nephritis is extremelyunusual (Table 1).
Implications forthePathogenesis of
Atoimmune Disease
SLE has long been considered primarily a
genetic disease (47). Clearly, hereditary fac-
tors are ofprimary importance in many cases
of the disease and in spontaneous mouse
models oflupus, where multiple disease sus-
ceptibility loci have been mapped (47,48).
However, the induction by pristane ofa dis-
ease closely resembling SLE in a variety of
mouse strains raises the possibility that envi-
ronmental agents could be important triggers
ofsporadic lupus. In addition to the BALB/c
and SJL strains presented here, C57BL/6,
DBA/1, DBA/2, A.SW, and other strains
develop lupus-specific autoantibodies and/or
nephritis afterpristane treatment (49).
Although the precise mechanism of the
induction ofautoimmune disease by pristane
remains unclear, we speculate that the injec-
tion ofpristane and other oils may stimulate
immunologic pathways mimicking those
involved in the idiopathic form ofthe dis-
ease. Identifying these pathways may shed
light on the pathogenesis ofspontaneous
lupus. The rapid uptake and/or encapsula-
tion (Figure 1B) ofpristane by phagocytic
cells argues that the initial defect may lie in
the response of these cells to the oil. That
possibility also is supported by the impor-
tance of macrophage-derived cytokines,
including IL-6 (12) and IL-12 (33), in the
development oflupus in pristane-treated
mice. The influx ofCD4+ T cells and B cells
into the lipogranulomas suggests that upon
contact with the oil, phagocytes may elabo-
rate factors (chemokine possibly) that recruit
additional cell populations. How the forma-
tion ofaggregates oflymphoid tissue in the
vicinity of the oil droplets creates a milieu
favoring the abrogation ofimmune tolerance
remains a central but unanswered question.
Addressing this question will undoubtedly
require a better understanding of the
immunotoxicologic properties ofpristane.
Immunotoxicology ofPristane
Pristane is a medium-chain-length isoprenoid
alkane with potent adjuvant activity found in
certain mineral oils (50) and derived from the
phytyl moiety ofchlorophyll (51). Pristane is
found ubiquitously throughout the environ-
ment, occurring in zooplankton, various geo-
logic sediments, and crude as well as marine
and freshwater fish oils. There has been consid-
erable interest in this substance ever since the
demonstration by Potter (52) and Anderson
(53) that injection ofmineral oil or pristane
causes plasmacytomas in certain strains ofmice
such as BALB/cPtAn. We recently found that
some, but not all, mineral oils can induce
lupus-specific autoantibodies in BALB/c mice
similar to those seen with pristane (54). The
ability ofmineral oil to promote autoantibody
formation may have public health implications
due to the significant human exposure to this
material in theenvironment.
The use of mineral oil and other paraf-
finoids is widespread in medications (e.g., lax-
atives, nose drops, petroleum jelly, baby oils),
as a protective coating for foods (e.g., apples,
cucumbers, cheese), for food packaging (e.g.,
milk, baked goods), and as a lubricant in bak-
ing (13,17,55,56). The average diet in the
United States contains 47.5 g ofmineral oil
annually (57,58). Human ingestion ofmineral
oil leads to partial absorption through the
intestine and transport to the portal lymph
nodes where oil granulomas similar to those in
pristane-treated mice form (13,14,16,58).
Inhalation ofmineral oil or other hydrocar-
bons causes lipoid pneumonia and the devel-
opment ofpulmonary lipogranulomas (59).
This disorder was common among children
until the Council on Pharmacy and Chemistry
removed nasal inhalant preparations contain-
ing petrolatum from the medications induded
in its list of"New and Nonofficial Remedies."
Mineral oil was replaced byothervehides such
as saline (59).
The ability of mineral oil to induce
autoimmunity in humans has not been stud-
ied extensively. However, there are controver-
sial reports ofadjuvant arthritis in humans
injected with hydrocarbons or silicone (60).
Hydrocarbon exposure also has been linked to
the development ofGoodpasture syndrome
with autoantibodies against components of
the glomerular basement membrane (61).
Silicone is similar in some respects to pristane:
both are inert, hydrophobic substances taken
up by phagocytic cells, both have been linked
to plasmacytoma induction in mice (62), and
both have been associated with autoimmu-
nity. Thus, there could be human analogs of
pristane-inducedlupus.
Conclusions
Although a variety ofchemicals and drugs
have been associated with the induction ofa
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lupuslike syndrome, pristane is the only
chemical that appears to cause a lupus syn-
drome with the typical clinical manifestations
(nephritis, serositis, arthritis) as well as char-
acteristic autoantibodies (anti-dsDNA, anti-
Sm, antiribosomal P). Thus, pristane induces
a more prototypical form ofthe disease than
procainamide, quinidine, hydralazine,
methyldopa, isoniazid, or minocycline.
Lupuslike disease appears to be induced
largely independent ofgenetic background,
although there are significant interstrain
differences in disease expression.
The onset oflupuslike disease in many
cases ofhuman SLE and in the spontaneous
murine models [(NZB/W)F1, MRL//pr,
BXSB] appears to be determined primarily
by heredity, with environmental factors
playing a secondary role. In contrast, the
onset ofpristane-induced lupus is triggered
primarily by exposure to a chemical, whereas
genetic factors modulate disease expression.
The chemical induction of a full-blown
lupus syndrome in mice that are not consid-
ered autoimmune prone raises the possibility
that chemical exposure to pristane or pris-
tanelike substances could account for certain
sporadic cases of lupus developing in
patients without a family history ofthe dis-
ease. Environmental exposure to alkanes,
paraffins, and other hydrocarbons is
common and could be an important trigger
ofautoimmunity in a subset ofpatients.
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